Literature DB >> 11230105

Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury.

M Remskar1, H Li, K Y Chyu, P K Shah, B Cercek.   

Abstract

Immune-mediator CD40 ligand is expressed on a variety of cell types involved in the immune response and on the cells of the vascular system. Inhibition of CD40 signaling has been associated with reduction of experimental atherosclerosis and transplant-associated vasculopathy. Immune response also plays a cardinal role in intimal thickening after acute arterial-wall injury. After carotid artery injury in CD40 ligand knockout (CD40L(-/-)) mice, the intimal thickening was increased 3-fold compared with the thickening in background B6/129 mice. The extent of thickening was similar to the thickening in B6/129 mice depleted of T lymphocytes with anti-CD4 and anti-CD8 antibodies. Injection of splenocytes from B6/129 mice into the CD40L(-/-) mice reduced the intimal thickening to the level comparable to the thickening in background B6/129 mice. These data suggest that CD40 signaling plays a significant role in the inhibitory effect of T lymphocytes on intimal thickening after arterial injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230105     DOI: 10.1161/01.res.88.4.390

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

1.  CD40/TRAF6 switch in neointimal hyperplasia.

Authors:  Nikolay Malinin; Tatiana Byzova
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

2.  NADPH oxidase in vascular injury: a new insight about its regulation and role in T cells.

Authors:  Jun-ichi Abe; Chang-Hoon Woo
Journal:  Circ Res       Date:  2009-01-30       Impact factor: 17.367

3.  The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling.

Authors:  Marjo M P C Donners; Linda Beckers; Dirk Lievens; Imke Munnix; Johan Heemskerk; Ben J Janssen; Erwin Wijnands; Jack Cleutjens; Alma Zernecke; Christian Weber; Cory L Ahonen; Ulrike Benbow; Andrew C Newby; Randolph J Noelle; Mat J A P Daemen; Esther Lutgens
Journal:  Blood       Date:  2008-01-14       Impact factor: 22.113

4.  The roles of buyang huanwu decoction in anti-inflammation, antioxidation and regulation of lipid metabolism in rats with myocardial ischemia.

Authors:  Yu Liu; Rong Lin; Xiaolian Shi; Zhiyuan Fang; Weirong Wang; Qinqin Lin; Jiye Zhang; Hui Zhang; Qiaoli Ji
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-10       Impact factor: 2.629

5.  Enhanced neointima formation following arterial injury in immune deficient Rag-1-/- mice is attenuated by adoptive transfer of CD8 T cells.

Authors:  Paul C Dimayuga; Kuang-Yuh Chyu; Jonathan Kirzner; Juliana Yano; Xiaoning Zhao; Jianchang Zhou; Prediman K Shah; Bojan Cercek
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

6.  CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury.

Authors:  Zifang Song; Rong Jin; Shiyong Yu; Joshua J Rivet; Susan S Smyth; Anil Nanda; D Neil Granger; Guohong Li
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

7.  Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects.

Authors:  K Okimura; K Maeta; N Kobayashi; M Goto; N Kano; T Ishihara; T Ishikawa; H Tsumura; A Ueno; Y Miyao; S Sakuma; F Kinugasa; N Takahashi; T Miura
Journal:  Am J Transplant       Date:  2014-04-14       Impact factor: 8.086

Review 8.  CD40 in coronary artery disease: a matter of macrophages?

Authors:  Matthijs F Jansen; Maurits R Hollander; Niels van Royen; Anton J Horrevoets; Esther Lutgens
Journal:  Basic Res Cardiol       Date:  2016-05-04       Impact factor: 17.165

9.  Distinct Differences on Neointima Formation in Immunodeficient and Humanized Mice after Carotid or Femoral Arterial Injury.

Authors:  Jill Moser; Joris van Ark; Marcory C van Dijk; Dale L Greiner; Leonard D Shultz; Harry van Goor; Jan-Luuk Hillebrands
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.